|Biotech Due Diligence||
Following the rejection of the Aveo Oncology $AVEO NDA for tivozanib in renal cell carcinoma by the FDA this spring, the company anounced a major restructuring and hosted a conference call. The attention from management and analysts on this call of course turned towards earlier stage pipeline opportunities and catalysts. See below for the highlights.
We The People vs. The Pharmaceutical Industry
Bernard Munos (Forbes)
Is Glyphosate Poisoning Everyone?
Derek Lowe (In the Pipeline)
FDA Patient Network
Doing my contractual duty...a new patient-focused web portal from FDA which has been getting good reviews so far
Deciphering the 10-K
The Financialist (hat tip to Josh Brown, one of the best follows on all of Twitter)
PhD Biopharma CEOs: Better, Bolder, Or Occasionally Lucky?
David Shaywitz (Forbes)
Lessons For Drug Development From The Aveo Buzzsaw
Luke Timmerman (Xconomy)
FDA: From Risk Aversion to Approval Activism
Ben Comer (PharmExec Blog)
4 Behavioral Biases And How To Avoid Them
How can Merck look itself in the mirror?
Josh Bloom (Medical Progress Today)
BiotechDueDiligence and HSP90 Central will be covering the 2013 AACR Annual Meeting live from Washington DC. This post will focus on abstracts to be presented by Astex Pharmaceuticals ASTX (partnered pipeline - see Parts 1 and 3 for internal ASTX assets), ArQule Inc ARQL, and BioSante Pharma BPAX.
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Very quick highlights from the Aveo Pharma $AVEO 2q-2012 conference call (Transcript via SeekingAlpha.)